Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype?
J Natl Cancer Inst
.
2016 Oct 28;109(2):djw218.
doi: 10.1093/jnci/djw218.
Print 2017 Feb.
Authors
Jisun Kim
1
,
Fresia Pareja
1
,
Britta Weigelt
1
,
Jorge S Reis-Filho
1
Affiliation
1
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
PMID:
27794126
DOI:
10.1093/jnci/djw218
No abstract available
Publication types
Editorial
Comment
MeSH terms
Breast Neoplasms*
Humans
Receptor, ErbB-2
Trastuzumab*
Substances
Receptor, ErbB-2
Trastuzumab